Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
NextCure appoints Garry Nicholson to board of directors » 07:43
03/30/20
03/30
07:43
03/30/20
07:43
NXTC

NextCure

$36.65 /

-1.17 (-3.09%)

, GTHX

G1 Therapeutics

$11.28 /

-0.71 (-5.92%)

NextCure (NXTC) announced…

NextCure (NXTC) announced the appointment of Garry Nicholson to its board of directors. In addition, Timothy M. Shannon, M.D. notified NextCure that he is stepping down from the company's board of directors. Nicholson currently serves as chairman of the board for G1 Therapeutics (GTHX) and as a board member for Turning Point Therapeutics, Five Prime Therapeutics, Personal Genome Diagnostics and Tmunity Therapeutics.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Syndax participates in a conference call with BTIG » 04:55
03/24/20
03/24
04:55
03/24/20
04:55
SNDX

Syndax

$9.13 /

+0.58 (+6.78%)

Conference call with…

Conference call with management to be held on March 24 hosted by BTIG.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Syndax participates in a conference call with BTIG » 11:30
03/23/20
03/23
11:30
03/23/20
11:30
SNDX

Syndax

$9.13 /

+0.58 (+6.78%)

Conference call with…

Conference call with management to be held on March 24 hosted by BTIG.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak » 06:52
03/23/20
03/23
06:52
03/23/20
06:52
PTCT

PTC Therapeutics

$39.72 /

+0.33 (+0.84%)

, SRPT

Sarepta

$86.81 /

-0.53 (-0.61%)

, IONS

Ionis Pharmaceuticals

$43.59 /

-2.41 (-5.24%)

, HALO

Halozyme

$15.57 /

+0.59 (+3.94%)

, MIRM

Mirum Pharmaceuticals

$11.43 /

+0.51 (+4.67%)

, DBVT

DBV Technologies

$3.63 /

+0.37 (+11.35%)

, SNDX

Syndax

$8.55 /

+0.035 (+0.41%)

, NERV

Minerva

$4.95 /

+0.11 (+2.27%)

, XFOR

X4 Pharmaceuticals

$8.44 /

-0.13 (-1.52%)

, MLND

Millendo Therapeutics

$6.01 /

+ (+0.00%)

, CBAY

CymaBay

$1.39 /

+0.09 (+6.92%)

Analyst Joel Beatty laid…

Analyst Joel Beatty laid out Citi's picks in SMid Biotech that are expected to be less negatively impacted from the coronavirus outbreak, and therefore should outperform relative to peers. The stocks picks are: PTC Therapeutics (PTCT), Sarepta (SRPT), Ionis Pharmaceuticals (IONS), Halozyme (HALO), Mirum Pharmaceuticals (MIRM), DBV Technologies (DBVT), Syndax (SNDX), Minerva (NERV), X4 Pharmaceuticals (XFOR), Millendo Therapeutics (MLND) and CymaBay (CBAY).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
G1 Therapeutics appoints Soma Gupta as CCO » 08:32
03/12/20
03/12
08:32
03/12/20
08:32
GTHX

G1 Therapeutics

$14.47 /

-2.23 (-13.35%)

, GSK

GlaxoSmithKline

$39.87 /

-1.15 (-2.80%)

, PFE

Pfizer

$32.16 /

-2.44 (-7.05%)

G1 Therapeutics announced…

G1 Therapeutics announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer. Bailey most recently served as President - U.S. at GlaxoSmithKline (GSK). Most recently, Gupta led the global commercial launch of Vyndaqel while serving as Vice President, Global Marketing for Amyloidosis and Cardiac Rare Disease at Pfizer (PFE). In connection with Ms. Gupta's appointment, the company is reporting an inducement option grant under Nasdaq Listing Rule 5635(c)(4). The compensation committee of the G1 Board of Directors has approved a non-qualified stock option award to purchase an aggregate of 300,000 shares of G1's common stock to Ms. Gupta. The option was granted outside of G1's Amended and Restated 2017 Employee, Director and Consultant Equity Plan as an inducement material to Ms. Gupta's acceptance of employment with G1. The stock option will have an exercise price equal to the closing price of G1's common stock on March 31, 2020. The option has up to a ten-year term and vests over four years, with 25% of the award vesting on the first anniversary of her employment, and as to an additional 1/48th of the shares monthly thereafter, subject to Ms. Gupta's continued service through the applicable vesting dates. John Demaree left his post as CCO to pursue other professional opportunities.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Karyopharm appoints John Demaree as CCO » 07:28
03/12/20
03/12
07:28
03/12/20
07:28
KPTI

Karyopharm

$21.34 /

-1.9 (-8.18%)

, GTHX

G1 Therapeutics

$14.47 /

-2.23 (-13.35%)

Karyopharm Therapeutics…

Karyopharm Therapeutics (KPTI) announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm's commercial strategy and operations, including the continued commercialization of oral XPOVIO, the Company's first-in-class, Selective Inhibitor of Nuclear Export compound. Prior to joining Karyopharm, Mr. Demaree served as Chief Commercial Officer at G1 Therapeutics (GT.HX)

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Syndax price target raised to $18 from $12 at Citi » 06:53
03/12/20
03/12
06:53
03/12/20
06:53
SNDX

Syndax

$11.75 /

-0.12 (-1.01%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty raised the firm's price target on Syndax Pharmaceuticals to $18 from $12 and keeps a Buy rating on the shares. The analyst believes the Phase 3 entinostat results in Q2 for metastatic breast cancer offer a favorable risk/reward. Furthermore, after the "encouraging" early data out of the developmental axatilimab and SNDX-5613 programs, the stock would still have $7 per share value if the entinostat trial were to fail, Beatty tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
Syndax upcoming Phase 3 readout will be 'clearing event, says Nomura Instinet » 08:14
03/05/20
03/05
08:14
03/05/20
08:14
SNDX

Syndax

$11.31 /

+2.07 (+22.40%)

Nomura Instinet analyst…

Nomura Instinet analyst Christopher Marai sees a "catalyst rich" 2020 for Syndax Pharmaceuticals. The analyst keeps a Buy rating on the shares with a $16 price target post the company's Q4 results. The Phase 3 entinostat readout will bring share upside, whether positive or negative, as it will be a "clearing event," Marai tells investors in a research note. Post the readout, investors can refocus attention on Syndax's "well-regarded" Menin inhibitor SNDX-5613 and chronic graft versus host disease program, contends the analyst.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Syndax price target raised to $27 from $20 at Baird » 07:51
03/04/20
03/04
07:51
03/04/20
07:51
SNDX

Syndax

$9.24 /

-0.52 (-5.33%)

Baird analyst Madhu Kumar…

Baird analyst Madhu Kumar raised the firm's price target on Syndax to $27 from $20 and keeps an Outperform rating on the shares. The anlayst said it proprietary cGVHD/Menin-MLL analyses reinforces the risk/reward profile for E2112 in Q2.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Syndax initiated with an Overweight at Barclays » 05:05
03/04/20
03/04
05:05
03/04/20
05:05
SNDX

Syndax

$9.24 /

-0.52 (-5.33%)

Barclays analyst Peter…

Barclays analyst Peter Lawson initiated coverage of Syndax Pharmaceuticals with an Overweight rating and $15 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.